Breaks Categories: News

FridayMay 17, 2024 2:52 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol (“CBD”), both alone and in combination in diabetic preconditioned rats. According to the announcement, several new areas of investigation are being explored in this study, including evaluating whether DehydraTECH-processed oral GLP-1 drugs are more effective than non-DehydraTECH-processed oral GLP-1 drugs in reaching brain tissue, improving weight loss and improving control of blood sugar. The study will also evaluate…

Continue Reading

TuesdayMay 14, 2024 3:37 pm

HempNewsBreaks – Zoned Properties Inc. (ZDPY) Releases Q1 2024 Financial Results Showing 22% Revenue Growth

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, including legalized cannabis, released its financial results for Q1 2024, the period ended March 31; the company also noted recent business highlights. According to the report, financial highlights include revenues totaling $837,052 for the quarter ended March 31, 2024, compared to $688,024 million revenues for the same quarter 2023, representing an increase of 22%; net income of $96,473, or $0.01 per fully diluted share, as compared to a net loss of $309,648, or ($0.03) per fully diluted share, for the same quarter in 2023, representing…

Continue Reading

TuesdayMay 14, 2024 2:34 pm

HempNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company’s strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through the third quarter of fiscal year 2024; the company’s subsidiary, 1st Detect, accepting orders for the TRACER 1000 Narcotics Trace Detector (“NTD”); the TRACER 1000 being listed in the U.S. General Services Administration (“GSA”) IT…

Continue Reading

FridayMay 10, 2024 2:44 pm

HempNewsBreaks – CannaCon West to Propel Growth of Cannabis Industry in Western US

CannaCon, a leading conference company, is announcing the CannaCon West Albuquerque. The event is set to take place on May 17-18, 2024, at the stunning Albuquerque Convention Center, Albuquerque. CannaCon West Albuquerque is one of several national CannaCon expos. It is designed to propel the growth of the cannabis industry in the western U.S., reverberate nationally, and create lasting value for years to come. According to the announcement, the two-day event paves the way to building a new industry paradigm in the western region of the U.S. by offering dynamic entrepreneurs expertise in raising seed capital, business and legal advice,…

Continue Reading

WednesdayMay 08, 2024 2:17 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database…

Continue Reading

MondayMay 06, 2024 3:14 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…

Continue Reading

WednesdayMay 01, 2024 2:19 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share; the shares and warrants were originally issued in October 2023 and February 2024, respectively. The company noted that following this exercise, there are no remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. According…

Continue Reading

MondayApr 29, 2024 2:43 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) CEO Featured Guest in Most Recent Bell2Bell Podcast

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, is spotlighted in the latest episode of the Bell2Bell Podcast, released from IBN. During the interview, GTVH president and CEO Steffan Dalsgaard talks with Bell2Bell host Stuart Smith about the company and Destino Ranch, its flagship project designed to be a tourist attraction, large immersive art installation and music festival venue; the ranch will be located about an hour from Las Vegas. As part of the development, Golden Triangle Ventures has purchased 70 acres and acquired ABI Create, one of the largest event developers in the country. In addition, Dalsgaard noted…

Continue Reading

ThursdayApr 25, 2024 1:00 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Subsidiary Establish Four-Pillar Business Model to Ensure Successful Development of Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment (or “Lavish”), have developed a comprehensive four-pillar business model. According to the announcement, the company intends for this key business component to be a critical component moving forward as Lavish Entertainment focuses on creating an industry-leading entertainment business. Specifically, the business model will be used as the company’s flagship project, Destino Ranch, is being developed. The new business model includes four essential key foundational elements: logistics, staffing, equipment and production. The company noted that these specific pillars were carefully identified and organized to complement…

Continue Reading

TuesdayApr 16, 2024 3:42 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to…

Continue Reading